Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages mdw559
Publisher
Oxford University Press (OUP)
Online
2016-10-22
DOI
10.1093/annonc/mdw559
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer
- (2016) Gerald S. Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
- (2016) Tatsuya Yoshida et al. JOURNAL OF CLINICAL ONCOLOGY
- RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
- (2014) K Tsuta et al. BRITISH JOURNAL OF CANCER
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
- (2013) Tony Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
- (2013) Oliver Gautschi et al. Journal of Thoracic Oncology
- Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma
- (2013) Heounjeong Go et al. LUNG CANCER
- Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
- (2013) Luca Mologni et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- RET Fusion Genes in Non–Small-Cell Lung Cancer
- (2012) Bo H. Chao et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
- (2012) Jin Soo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer Cells
- (2011) Hans H. G. Verbeek et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More